8-K: Outset Medical Cuts 2025 Revenue Outlook Amid Deal Delays

Outset Medical reported third-quarter results, revising its 2025 revenue guidance downwards due to shifted timing for large customer opportunities.

Summary

• Net revenue for the third quarter of 2025 was $29.4 million, representing a 3% increase from $28.7 million in the prior-year period.
• Tablo console revenue grew by 8% from the prior-year period.
• Recurring revenue, comprising Tablo consumables and services, was $21.1 million, a slight increase from the prior-year period, with consumable revenue impacted by order timing in Q3 but accelerating in Q4.
• GAAP gross margin reached 39.4%, compared to 34.3% in Q3 2024, while non-GAAP gross margin was 39.9%, expanding 3.5 percentage points over the prior-year period.
• Operating expenses declined nearly 20% from the third quarter of 2024 to $27.4 million.
• The company used less than $6 million of cash during the quarter, ending with approximately $182 million in total cash and short-term investments.
• Revised 2025 revenue guidance to a range of $115 million to $120 million, down from the previous range of $122 million to $126 million.
• Non-GAAP gross margin guidance for 2025 remains unchanged, still expected to be in the high-30% range.
• Expects to use less than $50 million of cash in 2025, a significant reduction compared to over $100 million used in 2024.
• GAAP net loss improved to $17.8 million in Q3 2025 from $27.9 million in Q3 2024, and non-GAAP net loss improved to $12 million from $20.2 million in Q3 2024.

Sentiment

Score: 4

Explanation: While the company demonstrated strong operational improvements in gross margin expansion and cash preservation, the downward revision of 2025 revenue guidance and the delay in closing key customer opportunities present a significant setback to growth expectations.

Positives

• Net revenue grew 3% year-over-year to $29.4 million in Q3 2025.
• Tablo console revenue increased by 8% from the prior-year period.
• Gross margin expanded significantly, reaching 39.4% (GAAP) and 39.9% (non-GAAP), up 5.1 and 3.5 percentage points respectively from Q3 2024.
• Operating expenses declined nearly 20% from Q3 2024, reflecting successful cost reduction actions.
• Cash usage significantly reduced, with less than $6 million used in Q3 2025, and a projection of less than $50 million for the full year 2025 (compared to over $100 million used in 2024).
• Exited Q3 2025 with nearly $182 million in total cash and short-term investments.
• Net loss improved to $17.8 million (GAAP) and $12 million (non-GAAP) in Q3 2025, from $27.9 million (GAAP) and $20.2 million (non-GAAP) in Q3 2024.
• Hospital demand for Tablo continues to grow due to clinical, operational, and financial benefits.

Negatives

• Revised 2025 revenue guidance downwards to $115 million to $120 million from a prior range of $122 million to $126 million.
• Recurring revenue increased only slightly from the prior-year period, with consumable revenue dampened by order timing in Q3.
• Expected timing to close several large opportunities forecasted for the second half of 2025 has shifted into Q4 2025 and early 2026.

Risks

• Actual results and other events may differ materially from forward-looking statements due to numerous risks and uncertainties.
• Factors that could cause actual results to differ materially are found in the Risk Factors section of public filings, including latest annual and quarterly reports.
• Ability to respond to and resolve any reports, observations, or other actions by the Food and Drug Administration or other regulators in a timely and effective manner.
• Impact of macroeconomic factors (including changes in tariff or trade laws and policies) on the company, its customers, and suppliers.

Future Outlook

Outset Medical revised its 2025 revenue guidance downwards to $115 million to $120 million, from a previous range of $122 million to $126 million, primarily due to the shifted timing of closing several large customer opportunities into the fourth quarter of 2025 and early 2026. The company maintains its non-GAAP gross margin guidance in the high-30% range and expects to significantly reduce cash usage in 2025 to less than $50 million, a substantial improvement from over $100 million used in 2024.

Management Comments

• "Hospital demand continues to grow as a result of the clinical, operational and financial benefits that can be achieved by insourcing dialysis with Outset’s proven technology, expert know-how and exceptional service."
• "We entered the second half of the year with work remaining in our commercial transformation, and while we have made good progress, the expected timing to close several large opportunities forecasted for the second half of 2025 has shifted."
• "These opportunities remain in the final stages of our sales process and are now expected to close over the fourth quarter and into early 2026."

Industry Context

Outset Medical operates in the medical technology sector, specifically focusing on transforming the dialysis experience with its Tablo Hemodialysis System. The company highlights growing hospital demand for insourcing dialysis, driven by the clinical, operational, and financial benefits of its technology. This suggests a trend towards more efficient and integrated dialysis solutions within healthcare facilities, potentially shifting away from traditional outsourced or less integrated models.

Legal Proceedings

• Litigation charges incurred outside of the ordinary course of business in connection with the stockholder class action and relative derivative lawsuits.

Stakeholder Impact

• Shareholders: Negative impact due to revised lower revenue guidance and delayed deals, potentially affecting stock price. Positive impact from improved profitability metrics and cash preservation.
• Customers (Hospitals): Continued growing demand for Tablo system, indicating positive reception of the product's benefits.
• Employees: Impacted by cost reduction actions and restructurings, as evidenced by severance and related charges.

Next Steps

• Hold a conference call on November 10, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to discuss Q3 2025 financial results.
• Continue efforts in commercial transformation.
• Work towards closing large customer opportunities in Q4 2025 and early 2026.
• Continued execution of initiatives designed to expand gross margins.
• Respond to and resolve any reports, observations, or other actions by the FDA or other regulators.

Key Dates

Recommendation

While Outset Medical demonstrated commendable progress in operational efficiency, gross margin expansion, and cash preservation, the downward revision of 2025 revenue guidance and the delay in closing significant customer deals introduce uncertainty regarding near-term growth. The market will likely react negatively to the reduced outlook. However, the underlying demand for their technology and the strategic focus on profitability offer a long-term positive. Investors should hold to monitor the successful closure of delayed deals and the continued execution of cost-saving and margin-expanding initiatives before making further investment decisions.

Keywords

Outset Medical, OM, dialysis, medical technology, Tablo Hemodialysis System, Q3 2025 earnings, revenue guidance, gross margin, operating expenses, cash flow, financial results, SEC filing, 8-K